Literature DB >> 15554555

P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women.

T Agorastos1, S Masouridou, A F Lambropoulos, S Chrisafi, D Miliaras, K Pantazis, T C Constantinides, A Kotsis, I Bontis.   

Abstract

The polymorphism of codon 72 in the p53 tumour suppressor gene has been associated in the last decade with the risk of developing various neoplasias. An influence of this polymorphism on ovarian and endometrial cancer has also been suggested. We examined the genotype frequency of this polymorphism in archival samples from 56 patients with endometrial neoplasias and 51 patients with ovarian neoplasias. Cervical smears from 30 healthy, human papillomavirus (HPV)-negative women with normal cytology and colposcopy, served as control sample. Women with ovarian neoplasias, especially adenocarcinomas, had Arg/Arg more often than healthy controls [odds ratio (OR) 4.16 at P = 0.0058]. No statistically significant difference was found between women with endometrial cancer and controls. Differentiation of ovarian tumours did not appear to be associated in a statistically significant manner with the genotype, whereas a positive linear trend of Arg/Arg towards poor differentiation was noted in endometrial malignancies (mainly endometrioid adenocarcinomas). Our results suggest that homozygous arginine at codon 72 of p53 may represent a risk factor for developing ovarian malignancies and may affect the differentiation of endometrial cancer. Further studies need to be carried out in order to establish the clinical use of this polymorphism for risk assessment and possibly outcome prediction of ovarian and endometrial neoplasias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554555     DOI: 10.1097/01.cej.0000136717.95465.09

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  16 in total

1.  Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.

Authors:  Su-Qin Shen; De-Ke Jiang; Guo-Yuan Liu; Fang Chen; Long Yu
Journal:  Mol Biol Rep       Date:  2011-09-28       Impact factor: 2.316

2.  TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.

Authors:  De-Ke Jiang; Lei Yao; Wei-Hua Ren; Wen-Zhang Wang; Bo Peng; Long Yu
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

3.  Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer.

Authors:  Joellen M Schildkraut; Ellen L Goode; Merlise A Clyde; Edwin S Iversen; Patricia G Moorman; Andrew Berchuck; Jeffrey R Marks; Jolanta Lissowska; Louise Brinton; Beata Peplonska; Julie M Cunningham; Robert A Vierkant; David N Rider; Georgia Chenevix-Trench; Penelope M Webb; Jonathan Beesley; Xiaoqing Chen; Catherine Phelan; Rebecca Sutphen; Thomas A Sellers; Leigh Pearce; Anna H Wu; David Van Den Berg; David Conti; Christopher K Elund; Rebecca Anderson; Marc T Goodman; Galina Lurie; Michael E Carney; Pamela J Thompson; Simon A Gayther; Susan J Ramus; Ian Jacobs; Susanne Krüger Kjaer; Estrid Hogdall; Jan Blaakaer; Claus Hogdall; Douglas F Easton; Honglin Song; Paul D P Pharoah; Alice S Whittemore; Valerie McGuire; Lydia Quaye; Hoda Anton-Culver; Argyrios Ziogas; Kathryn L Terry; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger; Brian Calingaert; Stephen Chanock; Mark Sherman; Montserrat Garcia-Closas
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

4.  Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.

Authors:  Elaine Cristina Morari; Andre Bacellar Costa Lima; Natassia Elena Bufalo; Janaina Luisa Leite; Fabiana Granja; Laura Sterian Ward
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-19       Impact factor: 4.553

5.  Profiling of Germline Mutations in Major Hotspot Codons of TP53 Using PCR-RFLP.

Authors:  B H Giridhar; S Vishwanath; Anirban Chakraborty
Journal:  Pathol Oncol Res       Date:  2018-03-02       Impact factor: 3.201

Review 6.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

7.  P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies.

Authors:  Shengming Dai; Chen Mao; Lijun Jiang; Guisheng Wang; Hongge Cheng
Journal:  Hum Genet       Date:  2009-04-09       Impact factor: 4.132

Review 8.  Genetic polymorphisms and endometrial cancer risk.

Authors:  Larissa A Meyer; Shannon N Westin; Karen H Lu; Michael R Milam
Journal:  Expert Rev Anticancer Ther       Date:  2008-07       Impact factor: 4.512

Review 9.  Role of genetic polymorphisms and ovarian cancer susceptibility.

Authors:  Peter A Fasching; Simon Gayther; Leigh Pearce; Joellen M Schildkraut; Ellen Goode; Falk Thiel; Georgia Chenevix-Trench; Jenny Chang-Claude; Shan Wang-Gohrke; Susan Ramus; Paul Pharoah; Andrew Berchuck
Journal:  Mol Oncol       Date:  2009-02-04       Impact factor: 6.603

10.  Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.

Authors:  Osamu Nunobiki; Masatsugu Ueda; Michiko Yamamoto; Eisaku Toji; Naomi Sato; Shinji Izuma; Yoshiaki Okamoto; Kiyo Torii; Sadamu Noda
Journal:  Hum Cell       Date:  2009-11       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.